Clinical trial · Observational
OncoSweep Cancer Spotlight and Spectrum Product Line
CONQUER Cancer Study: To Collect Blood Samples From Cancer and Non-cancer Participants for Development and Validation of the 'OncoSweep Cancer Spotlight and Spectrum Product Line
NCT06261294CI-TRIAL-00095281completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
CONQUER cancer study: To collect blood samples from cancer and non-cancer participants for development and validation of the 'OncoSweep Cancer Spotlight and Spectrum Product Line'
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OncoSweep Lung Spotligh | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- two group Study arm determination based
- description
- Subjects will be assigned into Test group or Control group based on the criteria: * Test group: Individual who has been diagnosed with lung nodule(s) or mass by his/ her healthcare provider utilizing LDCT or CT scan and has already scheduled for interventional procedure; * Control group: Individual is willing to undergo COPD examination and LDCT or CT scan with 3-5 mm spatial z-axis resolution and has no findings from the scan and examination
- interventionNames
- Diagnostic Test: OncoSweep Lung Spotligh
Primary outcomes (1)
- measure
- To differentiate lung cancer signals from non-cancer signals based on analysis of OncoSweep Lung Spotlight.
- timeFrame
- two years
- description
- To compare blood samples from lung cancer cases and non-cancer control subjects to develop and evaluate:1.Cancer models for discriminating lung cancer versus non-cancer 2.Platform evaluation 3.Data storage and algorithm establishment for further cancer research
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:
* Inclusion
1. Individual who is not mentally impaired, capable to read, understand, and is willing to provide signed and dated informed consent form.
2. Individual is aged 18 years old or above.
3. Individual who is willing to provide information on the given questionnaire. Test group: Individual was diagnosed with pulmonary nodules or masses by low-dose CT (LDCT)/ CT, and evaluated by the physician needed to conduct a biopsy or/ and surgery has been arranged.
Control group: Individual is willing to undergo LDCT or CT scan with 3-5 mm spatial z-axis resolution, pulmonary function examination, X-ray, laboratory blood test, and blood drawing.
4. Control group: Individual has no abnormal finding from LDCT or CT scan with 3-5 mm spatial z-axis resolution and pulmonary function examination(FEV1/FVC Ratio≧70%).
5. Individual did not donate blood or receive blood transfusion within two months before joining the study.
Exclusion Criteria:
* Exclusion
1. Individual who is not suitable for participating as per Investigator's judgement.
2. Individual who has undergone gene therapy or related product within one year prior to enrolling in this study.
3. Individual who is attending another clinical study at the time of enrollment.
4. Individual who is known to be pregnant.
5. Individual who has received a vaccine within two weeks.
6. Individual who has a history of any cancer occurrences other than lung cancer.References
Publications (0)
Data not yet available
No reference posted for this study.